Search the Newsreel

Earnings call transcript: BioCardia posts q2 2026 loss beat, shares rise after hours

BioCardia (BCDA) reported a smaller-than-expected Q2 2026 loss of $0.13 per share, beating analyst estimates of $0.18, and its shares rose in after-hours trading. The company highlighted significant regulatory progress, including support from Japan's PMDA for a Shonin submission for CardiAMP cell therapy and …

Is BioCardia Inc (BCDA) Facing Financial Challenges After Q2 Ear

BioCardia, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

BRIEF-BioCardia, Inc. Q2 Net Income USD -1.613 Million

BioCardia, Inc. reported a Q2 net income of USD -1.613 million. The article from Reuters provides a brief update on the company's financial performance. Full access to this and other news sources is available through a TradingView subscription.

BioCardia reports Q2 2026 net loss narrows to $1.6M; cash $4.1M with runway into 2027

BioCardia (BCDA) reported a net loss of $1.6 million for Q2 2026, a reduction from $2.0 million in the prior year, and holds $4.1 million in cash, projecting a runway into 2027. The company is actively pursuing regulatory approvals in Japan and the US …

BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results

BioCardia, Inc. reported its second-quarter 2026 financial results, highlighting significant progress in regulatory discussions with agencies in Japan and the U.S. The company achieved important milestones including PMDA support for CardiAMP Cell Therapy submission in Japan, FDA acknowledgement that the CardiAMP HF II trial …

BioCardia, Inc. Revenue Breakdown – NASDAQ:BCDA

This article provides a title for a financial breakdown of BioCardia, Inc. (NASDAQ:BCDA) but contains no actual content regarding revenue figures or analysis. Instead, it features navigation elements, market data disclaimers, and links related to the TradingView platform. The page appears to be a …

BioCardia Inc expected to post a loss of 18 cents a share - Earnings Preview

BioCardia Inc is anticipated to report a loss of 18 cents per share, according to this earnings preview. The article from Reuters provides this financial projection for the company. Readers can access the full article through a TradingView subscription.

BioCardia (BCDA.US) will release its earnings report on August 12.

BioCardia (BCDA.US) has announced that it will be releasing its earnings report on August 12. Investors and analysts will be watching closely for the company's financial performance.

BioCardia Inc (BCDA) Stock News Today

This article provides an update on BioCardia Inc (BCDA) stock, noting its current trading price and a slight decline. It indicates that more news regarding earnings, analyst ratings, and key developments will be available soon. The piece highlights that the content is primarily a …

BioCardia Inc (BCDA) Earnings Forecast: Future EPS & Revenue Growth Estimates

BioCardia Inc (BCDA) has an earnings forecast score of 8.00, ranking 171 out of 387 in the Biotechnology & Medical Research industry. Analysts provide an average price target of $15.50 for BCDA, with a high of $25.00 and a low of $6.00, indicating a …

Insiders In BioCardia Still Down 21% On US$1.08m Investment

Insiders at BioCardia, Inc. (NASDAQ:BCDA) are still down 21% on their US$1.08 million investment from the last year, despite a recent 23% stock gain. The largest purchase was by Independent Director Simon Stertzer for US$498k at US$1.25 per share, higher than the current US$0.95, …

BioCardia to Report Second Quarter 2026 Financial Results and Provide Corporate Update on August 12 Conference Call

BioCardia, Inc. will host a conference call on August 12, 2026, at 4:30 PM EDT to discuss its second-quarter 2026 financial results and provide a corporate update. The call will include a presentation, a Q&A session, and will be accessible via registration, dial-in numbers, …

BioCardia Sets Live Webcast for Q2 Results on Aug. 12

BioCardia (NASDAQ:BCDA) will host a conference call on Wednesday, August 12, 2026, at 4:30 PM EDT to discuss its Q2 2026 financial results and provide a corporate update. Investors can register online for dial-in details or join by phone or live webcast, with replays …

BioCardia (BCDA) Q1 2026 Earnings: Wider EPS Loss of $0.21 Misses Estimates, Yet Stock Climbs 5.04%

BioCardia CEO Peter Altman buys $3,900 in common stock

BioCardia CEO Peter Altman purchased 5,000 shares of the company's common stock for $3,900 on July 29, 2026, at a weighted average price of $0.78 per share. This transaction occurred while the stock was trading near its 52-week low, and InvestingPro analysis suggests it …

Form 4 Biocardia Inc For: 29 July By Investing.com

This article reports on a Form 4 filing for Biocardia Inc (BCDA) related to activities on July 29, consistent with insider trading disclosures. The article is a brief announcement from Investing.com, typical of filings news. No specific details of the Form 4 are provided …

BioCardia (NASDAQ: BCDA) CEO buys 5,000 shares at $0.78

BioCardia, Inc. (NASDAQ: BCDA) President and CEO Peter Altman purchased 5,000 shares of common stock on July 29, 2026, at a weighted average price of $0.78 per share. The transaction, executed in multiple trades between $0.77 and $0.80, increases his direct holdings to 373,885 …

BCDA|BioCardia Inc|Price:0.795|Chg%:-0.013

This article provides a comprehensive stock analysis of BioCardia Inc (BCDA) from TradingKey, highlighting its strong fundamentals and high growth potential despite recent weak stock market performance. The company is developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with product candidates in …

BioCardia Inc (BCDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for BioCardia Inc (BCDA), focusing on business segments and regional contributions. However, it indicates that relevant data for these categories have not yet been disclosed by the company. The page also displays current stock information and market cap …

BioCardia Inc (BCDA) Cash Flow

The article provides a detailed cash flow statement for BioCardia Inc (BCDA), including operating, investing, and financing cash flows, with data presented quarterly and annually. It highlights key financial figures such as BioCardia Inc's operating cash flow of -7.44M in fiscal year 2025 and …

BioCardia Inc (BCDA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of BioCardia Inc (BCDA), outlining both major individual and institutional holdings. It provides a breakdown of shareholder types, including individual investors, corporations, and hedge funds, and tracks changes in institutional shareholding over several quarters. The report also lists …

BioCardia, Inc. Revenue Breakdown – FWB:6JU0

This article provides a financial overview and revenue breakdown for BioCardia, Inc. (FWB:6JU0) on the Frankfurt Stock Exchange. It highlights access to fundamental statistics, statements, dividends, earnings, and segment performance information for the company. The page appears to be a financial data portal, offering …

BioCardia Inc (BCDA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of BioCardia Inc (BCDA), noting its current valuation score is 8.87, placing it 86th out of 386 in the Biotechnology & Medical Research industry. The company's P/E ratio is reported at -0.99, which is significantly below its recent …

BioCardia (BCDA) CEO Peter Altman purchases 500 shares in July 17 trade

BioCardia, Inc.'s President & CEO, Peter Altman, purchased 500 shares of common stock on July 17, 2026, at $0.83 per share in an open-market transaction. This purchase increased his direct holdings to 368,885 shares of BioCardia common stock. The transaction was not made under …

BioCardia CEO Peter Altman buys $3,754 in company stock

BioCardia CEO Peter Altman recently purchased 4,300 shares of company common stock for a total of $3,754, with individual share prices ranging from $0.86 to $0.88. This insider buying occurred despite a recent decline in the stock's value, which has fallen 16.91% in the …

BioCardia (BCDA) Q1 2026 Earnings Transcript

BioCardia, Inc. Q1 2026 Earnings Call Summary

BIOCARDIA ($BCDA) Releases Q4 2025 Earnings

BioCardia Sets Major March Catalyst: 2024 Earnings Plus Pivotal Heart Trial Data